<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984398</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-110</org_study_id>
    <nct_id>NCT01984398</nct_id>
  </id_info>
  <brief_title>Comparison of Two Formulations of Androxal</brief_title>
  <official_title>A Double-Blind Crossover Study In Healthy Volunteers to Compare Two Formulations of Androxal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine and compare the pharmacokinetics (PK) of a single dose of each of two
      formulations Androxal
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine and compare the pharmacokinetics (PK) of a single dose of each of two
      formulations of 12.5 mg and 25 mg Androxal administered to healthy male volunteers, and to
      determine and compare the safety of a single dose each of two formulations of 12.5 mg and 25
      mg Androxal administered to healthy male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2013</start_date>
  <completion_date type="Actual">December 31, 2013</completion_date>
  <primary_completion_date type="Actual">December 31, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Androxal Cmax Formulation A</measure>
    <time_frame>24 hours</time_frame>
    <description>To determine and compare the pharmacokinetic parameter Cmax between two formulations of Androxal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Androxal Cmax Formulation B</measure>
    <time_frame>24 hours</time_frame>
    <description>To determine and compare the PK parameter Cmax between two formulations of Androxal</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>12.5 mg Androxal (formulations A and B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg Androxal (formulations A and B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg Androxal Formulation A</intervention_name>
    <description>Single dose of 12.5 mg Androxal formulation A</description>
    <arm_group_label>12.5 mg Androxal (formulations A and B)</arm_group_label>
    <other_name>enclomiphene citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg Androxal Formulation B</intervention_name>
    <description>Single dose of 12.5 mg Androxal Formulation B</description>
    <arm_group_label>12.5 mg Androxal (formulations A and B)</arm_group_label>
    <other_name>enclomiphene citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg Androxal Formulation A</intervention_name>
    <description>Single dose of 25 mg Androxal formulation A</description>
    <arm_group_label>25 mg Androxal (formulations A and B)</arm_group_label>
    <other_name>enclomiphene citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg Androxal Formulation B</intervention_name>
    <description>Single dose of 25 mg Androxal formulation B</description>
    <arm_group_label>25 mg Androxal (formulations A and B)</arm_group_label>
    <other_name>enclomiphene citrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Speaks, reads, and understands English or Spanish and is willing and able to provide
             written informed consent on an Institutional Review Board (IRB)-approved form prior to
             the initiation of any study procedures;

          -  Male, between the ages of 18-60 years;

          -  No significant abnormal findings at the screening physical examination as evaluated by
             the Investigator;

          -  Normal laboratory values (or abnormal but not clinically significant) at screening as
             determined by the Investigator;

          -  Subject is willing to remain in the clinic overnight for the Day 1 and Day 6 visits;

          -  Must be able to swallow gelatin capsules

        Exclusion Criteria:

          -  Known hypersensitivity to Clomid;

          -  Abnormal screening visit vital signs or clinical laboratory evaluation considered
             clinically significant by the Investigator;

          -  Subject with a significant organ abnormality or disease as determined by the
             Investigator;

          -  Any medical condition that would interfere with the study as determined by the
             Investigator;

          -  Slow Cytochrome P4502D6 (CYP2D6) metabolizer

          -  Participation in a clinical trial with investigational medication within 30 days prior
             to study medication administration;

          -  An acute illness within 5 days of study medication administration;;

          -  A mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study and/or evidence of an uncooperative attitude, as
             determined by the Investigator;

          -  History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary
             embolism);

          -  History of myocardial infarction, unstable angina, symptomatic heart failure,
             ventricular dysrhythmia, or known history of (corrected QT) QTc interval prolongation;

          -  An employee or family member of an employee of the study site or the Sponsor.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Chan</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>30014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.reprosrx.com</url>
    <description>Sponsor Corporate Website</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <results_first_submitted>June 26, 2014</results_first_submitted>
  <results_first_submitted_qc>May 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2019</results_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>12.5 mg Androxal (Formulation A), Then B</title>
          <description>During Treatment Period 1, participants were randomly assigned to a single dose of either 12.5 mg Androxal Formulation A or 12.5 mg Androxal Formulation B.
After the washout period, participants then crossed over to receive the alternate 12.5 mg formulation during Treatment Period 2, ensuring all participants had received one dose of Formulation A and one dose of Formulation B.</description>
        </group>
        <group group_id="P2">
          <title>12.5 mg Androxal (Formulation B), Then A</title>
          <description>During Treatment Period 1, participants were randomly assigned to a single dose of either 12.5 mg Androxal Formulation A or 12.5 mg Androxal Formulation B.
After the washout period, participants then crossed over to receive the alternate 12.5 mg formulation during Treatment Period 2, ensuring all participants had received one dose of Formulation A and one dose of Formulation B.</description>
        </group>
        <group group_id="P3">
          <title>25 mg Androxal (Formulation A), Then B</title>
          <description>During Treatment Period 1, participants were randomly assigned to a single dose of either 25 mg Androxal formulation A or 25 mg Androxal formulation B.
After the washout period, participants then crossed over to receive the alternate 25 mg formulation during Treatment Period 2, ensuring all participants had received one dose of Formulation A and one dose of Formulation B.</description>
        </group>
        <group group_id="P4">
          <title>25 mg Androxal (Formulation B), Then A</title>
          <description>During Treatment Period 1, participants were randomly assigned to a single dose of either 25 mg Androxal formulation A or 25 mg Androxal formulation B.
After the washout period, participants then crossed over to receive the alternate 25 mg formulation during Treatment Period 2, ensuring all participants had received one dose of Formulation A and one dose of Formulation B.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period of 5 to 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population</population>
      <group_list>
        <group group_id="B1">
          <title>12.5 mg Androxal (Formulations A and B)</title>
          <description>During Treatment Period 1, participants were randomly assigned to a single dose of either 12.5 mg Androxal Formulation A or 12.5 mg Androxal Formulation B.
After the washout period, participants then crossed over to receive the alternate 12.5 mg formulation during Treatment Period 2, ensuring all participants had received one dose of Formulation A and one dose of Formulation B.</description>
        </group>
        <group group_id="B2">
          <title>25 mg Androxal (Formulations A and B)</title>
          <description>During Treatment Period 1, participants were randomly assigned to a single dose of either 25 mg Androxal formulation A or 25 mg Androxal formulation B.
After the washout period, participants then crossed over to receive the alternate 25 mg formulation during Treatment Period 2, ensuring all participants had received one dose of Formulation A and one dose of Formulation B.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" spread="7.5"/>
                    <measurement group_id="B2" value="37.8" spread="6.1"/>
                    <measurement group_id="B3" value="37.7" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Androxal Cmax Formulation A</title>
        <description>To determine and compare the pharmacokinetic parameter Cmax between two formulations of Androxal</description>
        <time_frame>24 hours</time_frame>
        <population>Safety and PK populations are the same</population>
        <group_list>
          <group group_id="O1">
            <title>12.5 mg Androxal Formulation A</title>
            <description>A single dose of 12.5 mg Androxal formulation A, received either during Treatment Period 1 or Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>25 mg Androxal Formulation A</title>
            <description>A single dose of 25 mg Androxal Formulation A, received either during Treatment Period 1 or Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Androxal Cmax Formulation A</title>
          <description>To determine and compare the pharmacokinetic parameter Cmax between two formulations of Androxal</description>
          <population>Safety and PK populations are the same</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.999" spread="0.349"/>
                    <measurement group_id="O2" value="1.67" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Androxal Cmax Formulation B</title>
        <description>To determine and compare the PK parameter Cmax between two formulations of Androxal</description>
        <time_frame>24 hours</time_frame>
        <population>Safety and PK populations are the same</population>
        <group_list>
          <group group_id="O1">
            <title>12.5 mg Androxal Formulation B</title>
            <description>A single dose of 12.5 mg Androxal formulation B, received either during Treatment Period 1 or Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>25 mg Androxal Formulation B</title>
            <description>A single dose of 25 mg Androxal formulation B, received either during Treatment Period 1 or Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Androxal Cmax Formulation B</title>
          <description>To determine and compare the PK parameter Cmax between two formulations of Androxal</description>
          <population>Safety and PK populations are the same</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.42"/>
                    <measurement group_id="O2" value="1.74" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 0 up to Day 8. (Up to 24 hours after last dose of study drug in Treatment Period 2)</time_frame>
      <desc>Adverse event data is presented for each Formulation (A and B) and dose (12.5mg and 25mg) of Androxal.</desc>
      <group_list>
        <group group_id="E1">
          <title>12.5 mg Androxal Formulation A</title>
          <description>A single dose of 12.5 mg Androxal formulation A, received either during Treatment Period 1 or Treatment Period 2.</description>
        </group>
        <group group_id="E2">
          <title>12.5mg Androxal Formulation B</title>
          <description>A single dose of 12.5 mg Androxal formulation B, received either during Treatment Period 1 or Treatment Period 2.</description>
        </group>
        <group group_id="E3">
          <title>25 mg Androxal Formulation A</title>
          <description>A single dose of 25 mg Androxal formulation A, received either during Treatment Period 1 or Treatment Period 2.</description>
        </group>
        <group group_id="E4">
          <title>25 mg Androxal Formulation B</title>
          <description>A single dose of 25 mg Androxal formulation B, received either during Treatment Period 1 or Treatment Period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor’s Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor’s Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

